Extended-release metformin hydrochloride: Single-composition osmotic tablet formulation

Treatments in Endocrinology

Volumn 3, Issue 5, 2004, Pages 327-332

  Wagstaff, Antona J ^a   Figgitt, David P ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIGUANIDE DERIVATIVE; EXTENDED RELEASE METFORMIN; METFORMIN; METFORMIN XT; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; AREA UNDER THE CURVE; DIABETES MELLITUS; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG COATING; DRUG HALF LIFE; DRUG RELEASE; DRUG TOLERABILITY; DYSPEPSIA; HUMAN; INSULIN RESISTANCE; LACTIC ACIDOSIS; MALABSORPTION; NAUSEA; PRIORITY JOURNAL; REVIEW; SUSTAINED RELEASE PREPARATION; TABLET FORMULATION;

DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; OSMOSIS;

EID: 4644252294     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200403050-00008     Document Type: Review

References (24)

1. Dunn CJ, Peters DH. Metformin: a review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 1995; 49 (5): 721-49
2. Bristol-Myers Squibb Company. Glucophage® XR (metformin hydrochloride extended-release tablets) prescribing information. Princeton (NJ): Bristol-Myers Squibb Company, 2003
3. Lamson M, Niecestro RM, Luckacsko P, et al. Pharmacokinetics of metformin XT versus immediate-release metformin [abstract no. 528-P]. Diabetes 2002 Jun; 51 (Suppl. 2): A131 (plus poster)
4. Abbasi F, Carantoni M, Chen Y-DI, et al. Further evidence for a central role of adipose tissue in the antihyperglycemic effect of metformin. Diabetes Care 1998 Aug; 21 (8): 1301-5
5. Niecestro R, Isaacsohn J, Sterman A, et al. Comparison of lipid control with 2000 and 2500 mg of metformin XT vs. immediate-release metformin in patients with type 2 diabetes [abstract no. 2142-PO]. Diabetes 2003 Jun; 52 (Suppl. 1): A494
6. Niecestro R, Luckacsko P, Walters E, et al. Safety and efficacy of metformin XT to immediate-release metformin in patients with type 2 diabetes [abstract no. 532-P]. Diabetes 2002 Jun; 51 (Suppl. 2): A131-2 (plus poster)
7. Mather KJ, Verma S, Anderson TJ. Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 2001 Apr; 37 (5): 1344-50
8. Yki-Järvinen H, Nikkilä K, Mäkimattila S. Metformin prevents weight gain by reducing dietary intake during insulin therapy in patients with type 2 diabetes mellitus (short communication). Drugs 1999; 58 Suppl. 1: 53-4
9. Tsaglis H, Ioannidis I, Giakoumaki A, et al. The effect of metformin on serum B12 levels: is there any clinical importance? [abstract no. 842] Diabetologia 1999 Aug; 42 (Suppl. 1): A224
10. Hoogeveen EK, Kostense PJ, Jakobs C, et al. Does metformin increase the serum total homocysteine level in non-insulin-dependent diabetes mellitus? J Intern Med 1997 Nov; 242: 389-94
11. Aarsand AK, Carlsen SM. Folate administration reduces circulating homocysteine levels in NIDDM patients on long-term metformin treatment. J Intern Med 1998 Aug; 244: 169-74
12. Davis TME, Jackson D, Davis WA, et al. The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: the Fremantle Diabetes Study. Br J Clin Pharmacol 2001 Aug; 52: 137-44
13. Lalau J-D, Race J-M. Lactic acidosis in metformin therapy. Drugs 1999: 58 Suppl. 1: 55-60
14. Cullen E, Niecestro RM, Lamson M, et al. Dose-exposure relationship of metformin XT [abstract no. 517-P]. Diabetes 2002 Jun; 51 (Suppl. 2): A128 (plus poster)
15. Cullen E, Liao J, Lukacsko P, et al. Pharmacokinetics and dose proportionality of extended-release metformin following administration of 1000, 1500, 2000 and 2500 mg in healthy volunteers. Biopharm Drug Dispos 2004 Sep; 25 (6): 261-3
16. Niecestro RM, Lukacsko P, Walters E, et al. Effects of food on the pharmacokinetics of metformin XT [abstract no. 531-P]. Diabetes 2002 Jun; 51 (Suppl. 2): A131 (plus poster)
17. Niecestro RM, Lukacsko P, Lamson MJ, et al. Pharmacokinetics of extended-release metformin versus immediate-release metformin in healthy subjects [abstract no. 53]. J Clin Pharmacol 2002 Sep; 42 (9): 1063 (plus poster)
18. Marathe PH, Wen Y, Norton J, et al. Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. Br J Clin Pharmacol 2000; 50: 325-32
19. Niecestro RM, Lukacsko P, Lamson MJ, et al. Multiple-dose pharmacokinetics of extended-release metformin [abstract no. 51]. J Clin Pharmacol 2002 Sep; 42 (9): 1062 (plus poster)
20. Niecestro RM, Kipnes M. Comparing efficacy and tolerability of metformin XT given daily to immediate-release metformin given twice daily in patients with type 2 diabetes [abstract no. 99]. Endocr Pract 2004; 10 (Suppl. 1): 34-35
21. Niecestro R, Lukacsko P, Walters E, et al. Safety and efficacy of 2000 and 2500 mg of metformin XT to immediate-release metformin in patients with type 2 diabetes [abstract no. 1907-PO]. Diabetes 2003 Jun; 52 (Suppl. 1): A440 (plus poster)
22. Kipnes M, Dandekar PK. Comparing the efficacy and tolerability of metformin XT qd to immediate-release metformin bid in patients with type 2 diabetes. Hackensack (NJ): Andrx Laboratories Inc., 2004. (Data on file)
23. Andrx Laboratories Inc. Fortamet™ (metformin hydrochloride extended-release tablets) prescribing information. Fort Lauderdale (FL): Andrx Laboratories Inc., 2004
24. Niecestro R, Sterman A, Friedhoff L, et al. Safety of metformin XT compared to immediate-release metformin [abstract no. 1908-PO]. Diabetes 2003 Jun; 52 (Suppl. 1): A440